Clinical-stage biopharma firm Longeveron Inc’s Lomecel-B treatment showed positive results for patients with mild Alzheimer’s disease and dementia, the company announced in a statement.
- Longeveron said the Lomecel-B Phase 1 study met its primary endpoint and was well tolerated without any safety concerns related to the treatment. It also indicated that patients were not reported to have developed serious side effects.
- The Mini Mental State Exam used to assess cognitive status showed the patients in the low-dose Lomecel-B group has a slower decline versus patients who were in the placebo group.
- Other tests also indicated that patients given the treatment show better quality of life versus the placebo six months after treatment, and an increase in the left hippocampus volume — critical for memory formation.
- Data also provided indications that support more exploration of Lomecel-B, particularly in its potential to slow down cognitive decline and improve the quality of life in patients with Alzheimer’s disease.
Data from the Alzheimer’s Association revealed that one in nine people aged 65 and above in the United States has dementia due to Alzheimer’s disease. LGVN is up 39.14%.